期刊文献+

28种药物联合氟康唑对白念珠菌体外抑菌作用的初步研究 被引量:6

In vitro interactions of 28 kinds of drugs with fluconazole against Candida albicans
下载PDF
导出
摘要 目的从常用免疫抑制剂、降血脂药、抗抑郁药、抗生素及非甾体类抗炎药中筛选出可能与氟康唑具有协同增效作用的药物。方法将5类28种药物配制成相同浓度(100μg/mL)后分别单独及与低浓度氟康唑联合加入白念珠菌耐药菌株(100、103)及敏感菌株(sc5314、y0109)菌悬液中,24 h(敏感菌)及48 h(耐药菌)后观察菌液澄清情况,菌液完全澄清为"+",混浊为"-",并重复上述实验3次。结果舍曲林等7种药物在该浓度下单用即可抑制所有实验菌株生长,与氟康唑合用后抑菌作用更加显著;利福喷丁等6种药物在该浓度下单用只能抑制敏感菌株生长,但与低浓度氟康唑合用后对耐药菌株也有抑制作用。结论舍曲林、利福喷丁等药物与氟康唑联合后对白念珠菌可能具有协同抑制作用。 Objective To screen the drugs which may have synergistic effects with fluconazole from 28 kinds of drugs including immunosuppressive agents,antilipemic agents,antidepressants,antibiotics and non-steroidal anti-inflammatory drugs.Methods 28 kinds of drugs within 5 main types were formulated intothe uniform concentrations of 100 μg/mL,then were dripped into the fungal suspensions of Candida albicans including fluconazole-resistant strains (100,103) and sensitive strains (sc5314,y0109),singly or together with fluconazole of low concentrations,respectively.Then the clarity of the fungal suspensions were observed respectively,the sensitive strains after 24 h,while the resistant strains after 48 h." + " was noted for the completely clarified cases,while "-" for the turbid cases accordingly.The test was repeated three times simultaneously.Results Sertraline and other 6 kinds of drugs could inhibit the growth of all the Candida albicans under the concentration of 100 μg/mL singly,which had more significant effects when combined with fluconazole.Rifapentine and other 5 kinds of drugs could only inhibit the growth of the sensitive strains under that concentration singly,but were still effective on the resistant strains when combined with fluconazole of low concentrations.Conclusion Some drugs such as sertraline,rifapentine may have synergistic inhibition effect on Candida albicans with fluconazole.
出处 《中国真菌学杂志》 CSCD 2013年第6期329-333,共5页 Chinese Journal of Mycology
基金 上海市浦东新区优秀青年医学人才培养项目(PWRq2012-06)
关键词 白念珠菌 药物 氟康唑 联合药敏 Candida albicans drugs fluconazole combined drug susceptibility testing
  • 相关文献

参考文献12

  • 1Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infec- tions[J]. Lancet Infect Dis,2011,11(2) :142-151.
  • 2Pfaller MA. Diekema DJ. Epidemiology of invasive candidiasis:a persistent public health problem[ J]. ClinMicrobiol Rev, 2007 , 20( 1 ) :133-163.
  • 3王惠平,刘全忠.白念珠菌对唑类抗真菌药物分子耐药机制的研究进展[J].中国麻风皮肤病杂志,2010,26(5):342-344. 被引量:1
  • 4Cabral ME, Figueroa LI, Farina JI. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae and Candida utilis-bioassays and ergosterol quantifica- tion [ J ]. Rev Iberoam Micol, 2013,30 ( 1 ) :31-38.
  • 5Menezes EA,VasconeelosJOnior AA,Silva CL,et al. In vitro syn- ergism of simvastatin and fluconazole against Candida species [ J ]. Rev Inst Med Trop Sao Paulo,2012 ,54 (4) : 197-199.
  • 6曹先伟,冀朝辉,李若瑜,付颖媛,王端礼.白色念珠菌对唑类抗真菌药物的耐药机制探讨[J].中华医院感染学杂志,2007,17(3):258-262. 被引量:18
  • 7Bink A, Kucharikovd S, Neirinek B, et al. The nonsteroidal an- tiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms [ J ]. Infect Dis, 2012,206( 11 ) :1790-1797.
  • 8Argenta JS, Alves SH, Silveira F, et al. In vitro and in vivo sus- ceptibility of two-drug and three-drug combinations of terbin- afine, itraconazole, caspofungin, ibuprofen and fluvastatin a- gainst Pythiuminsidiosum [ J ]. Vet Microbiol, 2012,157 ( 1-2 ) : 137-142.
  • 9Kofla G, Turner V, Schulz B, et al. Doxorubicin induces drug ef- flux pumps in Candida albicans [J]. Med Mycol,2011,49(2) : 132-142.
  • 10Zhai B, Wu C,Wang L, et al. The antidepressant sertraline pro- vides a promising therapeutic option for neurotropic Cryptococcal infections [ J ]. Antimicrob Agents Chemother, 2012,56 ( 7 ) : 3758 -3766.

二级参考文献20

  • 1郭慧君,夏忠弟.白色念珠菌耐药蛋白(Cdr1p)表达及调控机制研究进展[J].国外医药(抗生素分册),2005,26(6):244-247. 被引量:2
  • 2Paulitsch A,Weger W,Ginter-Hanselmayer G,et al.A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz,Austria.Mycoses 2006;49(6):471-475.
  • 3Lamb DC,Kelly DE,Schunck WH,et al.The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity.J Bio Chem 1997;272(9):5682-5688.
  • 4Chau AS,Mendrick CA,Sabatelli FJ,et al.Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.Antimicro Agents Chemother 2004; 48(6):2124-2131.
  • 5Perea S,Lopez-Ribot JL,Kirkpatrick WR,et al.Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.Antimicro Agents Chemother 2001;45(10):2676-2684.
  • 6White TC,Holleman S,Dy F,et al.Resistance mechanisms in clinical isolates of Candida albicans.Antimicro Agents Chemother 2002;46(6):1704-1713.
  • 7Cernicka J,Subik J.Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis.Int J Antimicrob Agents 2006;27(5):403-408.
  • 8Xu Y,Chen L,Li C.Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations.J Antimic Chem 2008;61(4):798-804.
  • 9Sanglard D,Ischer F,Parkinson T,et al.Candida albicans mutations in the ergosterol biosynthetic pathway andresistance to several antifungal agents.Antimicrob Agents Chemother 2003;47:2404-2412.
  • 10Marr KA,Lyons CN,Ha K,et al.Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.Antimicrob Agents Chemother 2001;45(1):52-59.

共引文献17

同被引文献40

  • 1曹红峰,宋靖芳,李国庆,黄文芳.中草药对嗜水气单胞菌ST-3-3抑菌作用的研究[J].中医药导报,2007,13(5):86-88. 被引量:40
  • 2路晓钦,黎莉华,周丽,刘利.白假丝酵母菌感染分布及耐药性分析[J].中国感染控制杂志,2007,6(6):419-421. 被引量:16
  • 3Pfaller MA , Diekema DJ. Epidemiology of invasive mycoses in North America [J]. Crit Rev Microbiol, 2010, 36( 1 ): 1-53.
  • 4Haider S, Rotstein C, Horn D, et al. The Prospective Antifungal Therapy Alliance registry: A two-centre Canadian experience [J]. Can J Infect Dis Med Microbiol, 2014, 25( 1 ): 17-23.
  • 5Azie N, Neofytos D, Pfaller M, et al. The PATH (Prospective Antifungal Theraphy) Alliance registry and invasive fungal infections:update 2012 [J]. Diagan Microbiol Infect Dis, 2012, 73 (4): 293-300.
  • 6Costerton JW, Geesey GG, Chcng KJ. How bacteria stick [J]. Sci Am,1978,238 ( 1 ): 86-95.
  • 7Ramage G, Mowat E, Jones B, et al. Our current understanding of fungal biofilms [J]. Crit Rev Microbiol, 2009, 35(4): 340-355.
  • 8Kucharikova S, Tournu H, Laqrou K, et al. Detailed comparison of Candida alhicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin [J]. J Med Microbiol, 2011,60(9): 1261-1269.
  • 9Cannon RD, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance [J]. Clin Microbiol Rev, 2009, 22 (2): 291-321.
  • 10Fauvart M, De Groote VN, Miehiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti- persister therapies [J]. J Med Micmbiol, 201 l, 60(6): 600-709.

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部